APO Research
Talk to an analyst

APO RESEARCH · REPORT

Swine Erysipelas Vaccine

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Swine Erysipelas Vaccine Market Outlook and Growth Opportunities 2026

2 January 2026198 pages

Choose your research edition.

Industry ResearchSwine Erysipelas Vaccine Industry Research Report 2026123 pages · $2,950 USDIndustry Growth & TrendsGlobal Swine Erysipelas Vaccine Industry Growth and Trends Forecast to 2032107 pages · $3,450 USDMarket StructureGlobal Swine Erysipelas Vaccine Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032193 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Swine Erysipelas Vaccine Market Outlook and Growth Opportunities 2026198 pages · $4,250 USDMarket Analysis & ForecastGlobal Swine Erysipelas Vaccine Market Analysis and Forecast 2026-2032199 pages · $4,950 USD

Market perspective

The global Swine Erysipelas Vaccine market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Swine Erysipelas Vaccine is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Swine Erysipelas Vaccine is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Swine Erysipelas Vaccine is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Swine Erysipelas Vaccine market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Swine Erysipelas Vaccine market include CAHIC, Zhejiang Shihua Nuo Beiwei Biotechnology Co., Ltd., Qilu Animal Health, Merck, Jiujiang Bomeilai Biological, Jilin Zhengye Biological, Hunan Zhong'an Biological Pharmaceutical Co., Ltd., Chengdu Tianbang Biology and Zoetis, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Swine Erysipelas Vaccine market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Swine Erysipelas Vaccine and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Swine Erysipelas Vaccine sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Swine Erysipelas Vaccine market size, projected growth trends, production technologies, key applications, and end-use industries.

Swine Erysipelas Vaccine Segment by Company

CAHIC

Zhejiang Shihua Nuo Beiwei Biotechnology Co., Ltd.

Qilu Animal Health

Merck

Jiujiang Bomeilai Biological

Jilin Zhengye Biological

Hunan Zhong'an Biological Pharmaceutical Co., Ltd.

Chengdu Tianbang Biology

Zoetis

Boehringer Ingelheim

Swine Erysipelas Vaccine Segment by Type

Live

Inactivated

Swine Erysipelas Vaccine Segment by Application

Pharmacy

Online Sale

Others

Swine Erysipelas Vaccine Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global Swine Erysipelas Vaccine status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Swine Erysipelas Vaccine market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Swine Erysipelas Vaccine significant trends, drivers, influence factors in global and regions.

6. To analyze Swine Erysipelas Vaccine competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Swine Erysipelas Vaccine market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Swine Erysipelas Vaccine and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Swine Erysipelas Vaccine.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Swine Erysipelas Vaccine market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Swine Erysipelas Vaccine industry.

Chapter 3: Detailed analysis of Swine Erysipelas Vaccine manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Swine Erysipelas Vaccine in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Swine Erysipelas Vaccine in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Swine Erysipelas Vaccine Industry Trends Table 2. Swine Erysipelas Vaccine Industry Drivers Table 3. Swine Erysipelas Vaccine Industry Opportunities and Challenges Table 4. Swine Erysipelas Vaccine Industry Restraints Table 5. Global Swine Erysipelas Vaccine Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Swine Erysipelas Vaccine Revenue Share by Company (2021-2026) Table 7. Global Swine Erysipelas Vaccine Sales Volume by Company (K Doses) & (2021-2026) Table 8. Global Swine Erysipelas Vaccine Sales Volume Share by Company (2021-2026) Table 9. Global Swine Erysipelas Vaccine Average Price (US$/Dose) of Company (2021-2026) Table 10. Global Swine Erysipelas Vaccine Company Ranking, (2024-2026) & (USD Million) Table 11. Global Swine Erysipelas Vaccine Key Company Manufacturing Base & Headquarters Table 12. Global Swine Erysipelas Vaccine Company, Product Type & Application Table 13. Global Swine Erysipelas Vaccine Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Swine Erysipelas Vaccine by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Live Table 18. Significant Companies of Inactivated Table 19. Global Swine Erysipelas Vaccine Sales Volume by Type 2021 VS 2025 VS 2032 (K Doses) Table 20. Global Swine Erysipelas Vaccine Sales Volume by Type (2021-2026) & (K Doses) Table 21. Global Swine Erysipelas Vaccine Sales Volume by Type (2027-2032) & (K Doses) Table 22. Global Swine Erysipelas Vaccine Sales Volume Share by Type (2021-2026) Table 23. Global Swine Erysipelas Vaccine Sales Volume Share by Type (2027-2032) Table 24. Global Swine Erysipelas Vaccine Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 25. Global Swine Erysipelas Vaccine Sales Value by Type (2021-2026) & (US$ Million) Table 26. Global Swine Erysipelas Vaccine Sales Value by Type (2027-2032) & (US$ Million) Table 27. Global Swine Erysipelas Vaccine Sales Value Share by Type (2021-2026) Table 28. Global Swine Erysipelas Vaccine Sales Value Share by Type (2027-2032) Table 29. Significant Companies of Pharmacy Table 30. Significant Companies of Online Sale Table 31. Significant Companies of Others Table 32. Global Swine Erysipelas Vaccine Sales Volume by Application 2021 VS 2025 VS 2032 (K Doses) Table 33. Global Swine Erysipelas Vaccine Sales Volume by Application (2021-2026) & (K Doses) Table 34. Global Swine Erysipelas Vaccine Sales Volume by Application (2027-2032) & (K Doses) Table 35. Global Swine Erysipelas Vaccine Sales Volume Share by Application (2021-2026) Table 36. Global Swine Erysipelas Vaccine Sales Volume Share by Application (2027-2032) Table 37. Global Swine Erysipelas Vaccine Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 38. Global Swine Erysipelas Vaccine Sales Value by Application (2021-2026) & (US$ Million) Table 39. Global Swine Erysipelas Vaccine Sales Value by Application (2027-2032) & (US$ Million) Table 40. Global Swine Erysipelas Vaccine Sales Value Share by Application (2021-2026) Table 41. Global Swine Erysipelas Vaccine Sales Value Share by Application (2027-2032) Table 42. Global Swine Erysipelas Vaccine Sales by Region: 2021 VS 2025 VS 2032 (K Doses) Table 43. Global Swine Erysipelas Vaccine Sales by Region (2021-2026) & (K Doses) Table 44. Global Swine Erysipelas Vaccine Sales Market Share by Region (2021-2026) Table 45. Global Swine Erysipelas Vaccine Sales by Region (2027-2032) & (K Doses) Table 46. Global Swine Erysipelas Vaccine Sales Market Share by Region (2027-2032) Table 47. Global Swine Erysipelas Vaccine Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 48. Global Swine Erysipelas Vaccine Sales Value by Region (2021-2026) & (US$ Million) Table 49. Global Swine Erysipelas Vaccine Sales Value Share by Region (2021-2026) Table 50. Global Swine Erysipelas Vaccine Sales Value by Region (2027-2032) & (US$ Million) Table 51. Global Swine Erysipelas Vaccine Sales Value Share by Region (2027-2032) Table 52. Global Swine Erysipelas Vaccine Market Average Price (US$/Dose) by Region (2021-2026) Table 53. Global Swine Erysipelas Vaccine Market Average Price (US$/Dose) by Region (2027-2032) Table 54. Global Swine Erysipelas Vaccine Sales by Country: 2021 VS 2025 VS 2032 (K Doses) Table 55. Global Swine Erysipelas Vaccine Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 56. Global Swine Erysipelas Vaccine Sales by Country (2021-2026) & (K Doses) Table 57. Global Swine Erysipelas Vaccine Sales Market Share by Country (2021-2026) Table 58. Global Swine Erysipelas Vaccine Sales by Country (2027-2032) & (K Doses) Table 59. Global Swine Erysipelas Vaccine Sales Market Share by Country (2027-2032) Table 60. Global Swine Erysipelas Vaccine Sales Value by Country (2021-2026) & (US$ Million) Table 61. Global Swine Erysipelas Vaccine Sales Value Market Share by Country (2021-2026) Table 62. Global Swine Erysipelas Vaccine Sales Value by Country (2027-2032) & (US$ Million) Table 63. Global Swine Erysipelas Vaccine Sales Value Market Share by Country (2027-2032) Table 64. CAHIC Company Information Table 65. CAHIC Business Overview Table 66. CAHIC Swine Erysipelas Vaccine Sales (K Doses), Value (US$ Million), Price (US$/Dose) and Gross Margin (2021-2026) Table 67. CAHIC Swine Erysipelas Vaccine Product Portfolio Table 68. CAHIC Recent Development Table 69. Zhejiang Shihua Nuo Beiwei Biotechnology Co., Ltd. Company Information Table 70. Zhejiang Shihua Nuo Beiwei Biotechnology Co., Ltd. Business Overview Table 71. Zhejiang Shihua Nuo Beiwei Biotechnology Co., Ltd. Swine Erysipelas Vaccine Sales (K Doses), Value (US$ Million), Price (US$/Dose) and Gross Margin (2021-2026) Table 72. Zhejiang Shihua Nuo Beiwei Biotechnology Co., Ltd. Swine Erysipelas Vaccine Product Portfolio Table 73. Zhejiang Shihua Nuo Beiwei Biotechnology Co., Ltd. Recent Development Table 74. Qilu Animal Health Company Information Table 75. Qilu Animal Health Business Overview Table 76. Qilu Animal Health Swine Erysipelas Vaccine Sales (K Doses), Value (US$ Million), Price (US$/Dose) and Gross Margin (2021-2026) Table 77. Qilu Animal Health Swine Erysipelas Vaccine Product Portfolio Table 78. Qilu Animal Health Recent Development Table 79. Merck Company Information Table 80. Merck Business Overview Table 81. Merck Swine Erysipelas Vaccine Sales (K Doses), Value (US$ Million), Price (US$/Dose) and Gross Margin (2021-2026) Table 82. Merck Swine Erysipelas Vaccine Product Portfolio Table 83. Merck Recent Development Table 84. Jiujiang Bomeilai Biological Company Information Table 85. Jiujiang Bomeilai Biological Business Overview Table 86. Jiujiang Bomeilai Biological Swine Erysipelas Vaccine Sales (K Doses), Value (US$ Million), Price (US$/Dose) and Gross Margin (2021-2026) Table 87. Jiujiang Bomeilai Biological Swine Erysipelas Vaccine Product Portfolio Table 88. Jiujiang Bomeilai Biological Recent Development Table 89. Jilin Zhengye Biological Company Information Table 90. Jilin Zhengye Biological Business Overview Table 91. Jilin Zhengye Biological Swine Erysipelas Vaccine Sales (K Doses), Value (US$ Million), Price (US$/Dose) and Gross Margin (2021-2026) Table 92. Jilin Zhengye Biological Swine Erysipelas Vaccine Product Portfolio Table 93. Jilin Zhengye Biological Recent Development Table 94. Hunan Zhong'an Biological Pharmaceutical Co., Ltd. Company Information Table 95. Hunan Zhong'an Biological Pharmaceutical Co., Ltd. Business Overview Table 96. Hunan Zhong'an Biological Pharmaceutical Co., Ltd. Swine Erysipelas Vaccine Sales (K Doses), Value (US$ Million), Price (US$/Dose) and Gross Margin (2021-2026) Table 97. Hunan Zhong'an Biological Pharmaceutical Co., Ltd. Swine Erysipelas Vaccine Product Portfolio Table 98. Hunan Zhong'an Biological Pharmaceutical Co., Ltd. Recent Development Table 99. Chengdu Tianbang Biology Company Information Table 100. Chengdu Tianbang Biology Business Overview Table 101. Chengdu Tianbang Biology Swine Erysipelas Vaccine Sales (K Doses), Value (US$ Million), Price (US$/Dose) and Gross Margin (2021-2026) Table 102. Chengdu Tianbang Biology Swine Erysipelas Vaccine Product Portfolio Table 103. Chengdu Tianbang Biology Recent Development Table 104. Zoetis Company Information Table 105. Zoetis Business Overview Table 106. Zoetis Swine Erysipelas Vaccine Sales (K Doses), Value (US$ Million), Price (US$/Dose) and Gross Margin (2021-2026) Table 107. Zoetis Swine Erysipelas Vaccine Product Portfolio Table 108. Zoetis Recent Development Table 109. Boehringer Ingelheim Company Information Table 110. Boehringer Ingelheim Business Overview Table 111. Boehringer Ingelheim Swine Erysipelas Vaccine Sales (K Doses), Value (US$ Million), Price (US$/Dose) and Gross Margin (2021-2026) Table 112. Boehringer Ingelheim Swine Erysipelas Vaccine Product Portfolio Table 113. Boehringer Ingelheim Recent Development Table 114. Key Raw Materials Table 115. Raw Materials Key Suppliers Table 116. Swine Erysipelas Vaccine Distributors List Table 117. Swine Erysipelas Vaccine Customers List Table 118. Research Programs/Design for This Report Table 119. Authors List of This Report Table 120. Secondary Sources Table 121. Primary Sources List of Figures Figure 1. Swine Erysipelas Vaccine Product Image Figure 2. Global Swine Erysipelas Vaccine Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Swine Erysipelas Vaccine Sales Value (2021-2032) & (US$ Million) Figure 4. Global Swine Erysipelas Vaccine Sales (2021-2032) & (K Doses) Figure 5. Global Swine Erysipelas Vaccine Sales Average Price (US$/Dose) & (2021-2032) Figure 6. Global Swine Erysipelas Vaccine Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Live Image Figure 10. Inactivated Image Figure 11. Global Swine Erysipelas Vaccine Sales Volume by Type (2021 VS 2025 VS 2032) & (K Doses) Figure 12. Global Swine Erysipelas Vaccine Sales Volume Share 2021 VS 2025 VS 2032 Figure 13. Global Swine Erysipelas Vaccine Sales Volume Share by Type (2021-2032) Figure 14. Global Swine Erysipelas Vaccine Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 15. Global Swine Erysipelas Vaccine Sales Value Share 2021 VS 2025 VS 2032 Figure 16. Global Swine Erysipelas Vaccine Sales Value Share by Type (2021-2032) Figure 17. Pharmacy Image Figure 18. Online Sale Image Figure 19. Others Image Figure 20. Global Swine Erysipelas Vaccine Sales Volume by Application (2021 VS 2025 VS 2032) & (K Doses) Figure 21. Global Swine Erysipelas Vaccine Sales Volume Share 2021 VS 2025 VS 2032 Figure 22. Global Swine Erysipelas Vaccine Sales Volume Share by Application (2021-2032) Figure 23. Global Swine Erysipelas Vaccine Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 24. Global Swine Erysipelas Vaccine Sales Value Share 2021 VS 2025 VS 2032 Figure 25. Global Swine Erysipelas Vaccine Sales Value Share by Application (2021-2032) Figure 26. Global Swine Erysipelas Vaccine Sales by Region: 2021 VS 2025 VS 2032 (K Doses) Figure 27. Global Swine Erysipelas Vaccine Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 28. Global Swine Erysipelas Vaccine Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 29. Global Swine Erysipelas Vaccine Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 30. North America Swine Erysipelas Vaccine Sales Value (2021-2032) & (US$ Million) Figure 31. North America Swine Erysipelas Vaccine Sales Value Share by Country (%), 2025 VS 2032 Figure 32. Europe Swine Erysipelas Vaccine Sales Value (2021-2032) & (US$ Million) Figure 33. Europe Swine Erysipelas Vaccine Sales Value Share by Country (%), 2025 VS 2032 Figure 34. Asia-Pacific Swine Erysipelas Vaccine Sales Value (2021-2032) & (US$ Million) Figure 35. Asia-Pacific Swine Erysipelas Vaccine Sales Value Share by Country (%), 2025 VS 2032 Figure 36. South America Swine Erysipelas Vaccine Sales Value (2021-2032) & (US$ Million) Figure 37. South America Swine Erysipelas Vaccine Sales Value Share by Country (%), 2025 VS 2032 Figure 38. Middle East & Africa Swine Erysipelas Vaccine Sales Value (2021-2032) & (US$ Million) Figure 39. Middle East & Africa Swine Erysipelas Vaccine Sales Value Share by Country (%), 2025 VS 2032 Figure 40. USA Swine Erysipelas Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 41. USA Swine Erysipelas Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 42. USA Swine Erysipelas Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 43. Canada Swine Erysipelas Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 44. Canada Swine Erysipelas Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 45. Canada Swine Erysipelas Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 46. Mexico Swine Erysipelas Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 47. Mexico Swine Erysipelas Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 48. Mexico Swine Erysipelas Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 49. Germany Swine Erysipelas Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 50. Germany Swine Erysipelas Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 51. Germany Swine Erysipelas Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 52. France Swine Erysipelas Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 53. France Swine Erysipelas Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 54. France Swine Erysipelas Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 55. U.K. Swine Erysipelas Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 56. U.K. Swine Erysipelas Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 57. U.K. Swine Erysipelas Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 58. Italy Swine Erysipelas Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 59. Italy Swine Erysipelas Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 60. Italy Swine Erysipelas Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 61. Spain Swine Erysipelas Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 62. Spain Swine Erysipelas Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 63. Spain Swine Erysipelas Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 64. Russia Swine Erysipelas Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 65. Russia Swine Erysipelas Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 66. Russia Swine Erysipelas Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 67. Netherlands Swine Erysipelas Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 68. Netherlands Swine Erysipelas Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 69. Netherlands Swine Erysipelas Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 70. Nordic Countries Swine Erysipelas Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 71. Nordic Countries Swine Erysipelas Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 72. Nordic Countries Swine Erysipelas Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 73. China Swine Erysipelas Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 74. China Swine Erysipelas Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 75. China Swine Erysipelas Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 76. Japan Swine Erysipelas Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 77. Japan Swine Erysipelas Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 78. Japan Swine Erysipelas Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 79. South Korea Swine Erysipelas Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 80. South Korea Swine Erysipelas Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 81. South Korea Swine Erysipelas Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 82. India Swine Erysipelas Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 83. India Swine Erysipelas Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 84. India Swine Erysipelas Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 85. Australia Swine Erysipelas Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 86. Australia Swine Erysipelas Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 87. Australia Swine Erysipelas Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 88. Southeast Asia Swine Erysipelas Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 89. Southeast Asia Swine Erysipelas Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 90. Southeast Asia Swine Erysipelas Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 91. Brazil Swine Erysipelas Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 92. Brazil Swine Erysipelas Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 93. Brazil Swine Erysipelas Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 94. Argentina Swine Erysipelas Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 95. Argentina Swine Erysipelas Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 96. Argentina Swine Erysipelas Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 97. Chile Swine Erysipelas Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 98. Chile Swine Erysipelas Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 99. Chile Swine Erysipelas Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 100. Colombia Swine Erysipelas Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 101. Colombia Swine Erysipelas Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 102. Colombia Swine Erysipelas Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 103. Peru Swine Erysipelas Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 104. Peru Swine Erysipelas Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 105. Peru Swine Erysipelas Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 106. Saudi Arabia Swine Erysipelas Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 107. Saudi Arabia Swine Erysipelas Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 108. Saudi Arabia Swine Erysipelas Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 109. Israel Swine Erysipelas Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 110. Israel Arabia Swine Erysipelas Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 111. Israel Arabia Swine Erysipelas Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 112. UAE Swine Erysipelas Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 113. UAE Swine Erysipelas Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 114. UAE Swine Erysipelas Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 115. Turkey Swine Erysipelas Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 116. Turkey Swine Erysipelas Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 117. Turkey Swine Erysipelas Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 118. Iran Swine Erysipelas Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 119. Iran Swine Erysipelas Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 120. Iran Swine Erysipelas Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 121. Egypt Swine Erysipelas Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 122. Egypt Swine Erysipelas Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 123. Egypt Swine Erysipelas Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 124. Swine Erysipelas Vaccine Value Chain Figure 125. Manufacturing Cost Structure Figure 126. Swine Erysipelas Vaccine Sales Mode & Process Figure 127. Direct Comparison with Distribution Share Figure 128. Distributors Profiles Figure 129. Years Considered Figure 130. Research Process Figure 131. Key Executives Interviewed

Scope & coverage.

Types
  • Live
  • Inactivated
Applications
  • Pharmacy
  • Online Sale
  • Others
Companies covered
  • CAHIC
  • Zhejiang Shihua Nuo Beiwei Biotechnology Co., Ltd.
  • Qilu Animal Health
  • Merck
  • Jiujiang Bomeilai Biological
  • Jilin Zhengye Biological
  • Hunan Zhong'an Biological Pharmaceutical Co., Ltd.
  • Chengdu Tianbang Biology
  • Zoetis
  • Boehringer Ingelheim

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Swine Erysipelas Vaccine Sales Value (2021-2032)
  4. 1.2.2 Global Swine Erysipelas Vaccine Sales Volume (2021-2032)
  5. 1.2.3 Global Swine Erysipelas Vaccine Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Swine Erysipelas Vaccine Market Dynamics
  1. 2.1 Swine Erysipelas Vaccine Industry Trends
  2. 2.2 Swine Erysipelas Vaccine Industry Drivers
  3. 2.3 Swine Erysipelas Vaccine Industry Opportunities and Challenges
  4. 2.4 Swine Erysipelas Vaccine Industry Restraints
3 Swine Erysipelas Vaccine Market by Company
  1. 3.1 Global Swine Erysipelas Vaccine Company Revenue Ranking in 2025
  2. 3.2 Global Swine Erysipelas Vaccine Revenue by Company (2021-2026)
  3. 3.3 Global Swine Erysipelas Vaccine Sales Volume by Company (2021-2026)
  4. 3.4 Global Swine Erysipelas Vaccine Average Price by Company (2021-2026)
  5. 3.5 Global Swine Erysipelas Vaccine Company Ranking (2024-2026)
  6. 3.6 Global Swine Erysipelas Vaccine Company Manufacturing Base and Headquarters
  7. 3.7 Global Swine Erysipelas Vaccine Company Product Type and Application
  8. 3.8 Global Swine Erysipelas Vaccine Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Swine Erysipelas Vaccine Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Swine Erysipelas Vaccine Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Swine Erysipelas Vaccine Market by Type
  1. 4.1 Swine Erysipelas Vaccine Type Introduction
  2. 4.1.1 Live
  3. 4.1.2 Inactivated
  4. 4.2 Global Swine Erysipelas Vaccine Sales Volume by Type
  5. 4.2.1 Global Swine Erysipelas Vaccine Sales Volume by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Swine Erysipelas Vaccine Sales Volume by Type (2021-2032)
  7. 4.2.3 Global Swine Erysipelas Vaccine Sales Volume Share by Type (2021-2032)
  8. 4.3 Global Swine Erysipelas Vaccine Sales Value by Type
  9. 4.3.1 Global Swine Erysipelas Vaccine Sales Value by Type (2021 VS 2025 VS 2032)
  10. 4.3.2 Global Swine Erysipelas Vaccine Sales Value by Type (2021-2032)
  11. 4.3.3 Global Swine Erysipelas Vaccine Sales Value Share by Type (2021-2032)
5 Swine Erysipelas Vaccine Market by Application
  1. 5.1 Swine Erysipelas Vaccine Application Introduction
  2. 5.1.1 Pharmacy
  3. 5.1.2 Online Sale
  4. 5.1.3 Others
  5. 5.2 Global Swine Erysipelas Vaccine Sales Volume by Application
  6. 5.2.1 Global Swine Erysipelas Vaccine Sales Volume by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Swine Erysipelas Vaccine Sales Volume by Application (2021-2032)
  8. 5.2.3 Global Swine Erysipelas Vaccine Sales Volume Share by Application (2021-2032)
  9. 5.3 Global Swine Erysipelas Vaccine Sales Value by Application
  10. 5.3.1 Global Swine Erysipelas Vaccine Sales Value by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Swine Erysipelas Vaccine Sales Value by Application (2021-2032)
  12. 5.3.3 Global Swine Erysipelas Vaccine Sales Value Share by Application (2021-2032)
6 Swine Erysipelas Vaccine Regional Sales and Value Analysis
  1. 6.1 Global Swine Erysipelas Vaccine Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Swine Erysipelas Vaccine Sales by Region (2021-2032)
  3. 6.2.1 Global Swine Erysipelas Vaccine Sales by Region: 2021-2026
  4. 6.2.2 Global Swine Erysipelas Vaccine Sales by Region (2027-2032)
  5. 6.3 Global Swine Erysipelas Vaccine Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Swine Erysipelas Vaccine Sales Value by Region (2021-2032)
  7. 6.4.1 Global Swine Erysipelas Vaccine Sales Value by Region: 2021-2026
  8. 6.4.2 Global Swine Erysipelas Vaccine Sales Value by Region (2027-2032)
  9. 6.5 Global Swine Erysipelas Vaccine Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Swine Erysipelas Vaccine Sales Value (2021-2032)
  12. 6.6.2 North America Swine Erysipelas Vaccine Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Swine Erysipelas Vaccine Sales Value (2021-2032)
  15. 6.7.2 Europe Swine Erysipelas Vaccine Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Swine Erysipelas Vaccine Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Swine Erysipelas Vaccine Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Swine Erysipelas Vaccine Sales Value (2021-2032)
  21. 6.9.2 South America Swine Erysipelas Vaccine Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Swine Erysipelas Vaccine Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Swine Erysipelas Vaccine Sales Value Share by Country, 2025 VS 2032
7 Swine Erysipelas Vaccine Country-level Sales and Value Analysis
  1. 7.1 Global Swine Erysipelas Vaccine Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Swine Erysipelas Vaccine Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Swine Erysipelas Vaccine Sales by Country (2021-2032)
  4. 7.3.1 Global Swine Erysipelas Vaccine Sales by Country (2021-2026)
  5. 7.3.2 Global Swine Erysipelas Vaccine Sales by Country (2027-2032)
  6. 7.4 Global Swine Erysipelas Vaccine Sales Value by Country (2021-2032)
  7. 7.4.1 Global Swine Erysipelas Vaccine Sales Value by Country (2021-2026)
  8. 7.4.2 Global Swine Erysipelas Vaccine Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Swine Erysipelas Vaccine Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Swine Erysipelas Vaccine Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Swine Erysipelas Vaccine Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Swine Erysipelas Vaccine Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Swine Erysipelas Vaccine Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Swine Erysipelas Vaccine Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Swine Erysipelas Vaccine Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Swine Erysipelas Vaccine Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Swine Erysipelas Vaccine Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Swine Erysipelas Vaccine Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Swine Erysipelas Vaccine Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Swine Erysipelas Vaccine Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Swine Erysipelas Vaccine Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Swine Erysipelas Vaccine Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Swine Erysipelas Vaccine Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Swine Erysipelas Vaccine Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Swine Erysipelas Vaccine Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Swine Erysipelas Vaccine Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Swine Erysipelas Vaccine Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Swine Erysipelas Vaccine Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Swine Erysipelas Vaccine Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Swine Erysipelas Vaccine Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Swine Erysipelas Vaccine Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Swine Erysipelas Vaccine Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Swine Erysipelas Vaccine Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Swine Erysipelas Vaccine Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Swine Erysipelas Vaccine Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Swine Erysipelas Vaccine Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Swine Erysipelas Vaccine Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Swine Erysipelas Vaccine Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Swine Erysipelas Vaccine Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Swine Erysipelas Vaccine Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Swine Erysipelas Vaccine Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Swine Erysipelas Vaccine Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Swine Erysipelas Vaccine Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Swine Erysipelas Vaccine Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Swine Erysipelas Vaccine Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Swine Erysipelas Vaccine Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Swine Erysipelas Vaccine Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Swine Erysipelas Vaccine Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Swine Erysipelas Vaccine Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Swine Erysipelas Vaccine Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Swine Erysipelas Vaccine Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Swine Erysipelas Vaccine Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Swine Erysipelas Vaccine Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Swine Erysipelas Vaccine Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Swine Erysipelas Vaccine Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Swine Erysipelas Vaccine Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Swine Erysipelas Vaccine Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Swine Erysipelas Vaccine Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Swine Erysipelas Vaccine Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Swine Erysipelas Vaccine Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Swine Erysipelas Vaccine Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Swine Erysipelas Vaccine Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Swine Erysipelas Vaccine Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Swine Erysipelas Vaccine Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Swine Erysipelas Vaccine Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Swine Erysipelas Vaccine Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Swine Erysipelas Vaccine Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Swine Erysipelas Vaccine Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Swine Erysipelas Vaccine Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Swine Erysipelas Vaccine Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Swine Erysipelas Vaccine Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Swine Erysipelas Vaccine Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Swine Erysipelas Vaccine Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Swine Erysipelas Vaccine Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Swine Erysipelas Vaccine Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Swine Erysipelas Vaccine Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Swine Erysipelas Vaccine Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Swine Erysipelas Vaccine Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Swine Erysipelas Vaccine Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Swine Erysipelas Vaccine Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Swine Erysipelas Vaccine Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Swine Erysipelas Vaccine Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Swine Erysipelas Vaccine Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Swine Erysipelas Vaccine Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Swine Erysipelas Vaccine Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Swine Erysipelas Vaccine Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Swine Erysipelas Vaccine Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Swine Erysipelas Vaccine Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Swine Erysipelas Vaccine Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Swine Erysipelas Vaccine Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Swine Erysipelas Vaccine Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Swine Erysipelas Vaccine Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 CAHIC
  2. 8.1.1 CAHIC Company Information
  3. 8.1.2 CAHIC Business Overview
  4. 8.1.3 CAHIC Swine Erysipelas Vaccine Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 CAHIC Swine Erysipelas Vaccine Product Portfolio
  6. 8.1.5 CAHIC Recent Developments
  7. 8.2 Zhejiang Shihua Nuo Beiwei Biotechnology Co., Ltd.
  8. 8.2.1 Zhejiang Shihua Nuo Beiwei Biotechnology Co., Ltd. Company Information
  9. 8.2.2 Zhejiang Shihua Nuo Beiwei Biotechnology Co., Ltd. Business Overview
  10. 8.2.3 Zhejiang Shihua Nuo Beiwei Biotechnology Co., Ltd. Swine Erysipelas Vaccine Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Zhejiang Shihua Nuo Beiwei Biotechnology Co., Ltd. Swine Erysipelas Vaccine Product Portfolio
  12. 8.2.5 Zhejiang Shihua Nuo Beiwei Biotechnology Co., Ltd. Recent Developments
  13. 8.3 Qilu Animal Health
  14. 8.3.1 Qilu Animal Health Company Information
  15. 8.3.2 Qilu Animal Health Business Overview
  16. 8.3.3 Qilu Animal Health Swine Erysipelas Vaccine Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Qilu Animal Health Swine Erysipelas Vaccine Product Portfolio
  18. 8.3.5 Qilu Animal Health Recent Developments
  19. 8.4 Merck
  20. 8.4.1 Merck Company Information
  21. 8.4.2 Merck Business Overview
  22. 8.4.3 Merck Swine Erysipelas Vaccine Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Merck Swine Erysipelas Vaccine Product Portfolio
  24. 8.4.5 Merck Recent Developments
  25. 8.5 Jiujiang Bomeilai Biological
  26. 8.5.1 Jiujiang Bomeilai Biological Company Information
  27. 8.5.2 Jiujiang Bomeilai Biological Business Overview
  28. 8.5.3 Jiujiang Bomeilai Biological Swine Erysipelas Vaccine Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Jiujiang Bomeilai Biological Swine Erysipelas Vaccine Product Portfolio
  30. 8.5.5 Jiujiang Bomeilai Biological Recent Developments
  31. 8.6 Jilin Zhengye Biological
  32. 8.6.1 Jilin Zhengye Biological Company Information
  33. 8.6.2 Jilin Zhengye Biological Business Overview
  34. 8.6.3 Jilin Zhengye Biological Swine Erysipelas Vaccine Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 Jilin Zhengye Biological Swine Erysipelas Vaccine Product Portfolio
  36. 8.6.5 Jilin Zhengye Biological Recent Developments
  37. 8.7 Hunan Zhong'an Biological Pharmaceutical Co., Ltd.
  38. 8.7.1 Hunan Zhong'an Biological Pharmaceutical Co., Ltd. Company Information
  39. 8.7.2 Hunan Zhong'an Biological Pharmaceutical Co., Ltd. Business Overview
  40. 8.7.3 Hunan Zhong'an Biological Pharmaceutical Co., Ltd. Swine Erysipelas Vaccine Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 Hunan Zhong'an Biological Pharmaceutical Co., Ltd. Swine Erysipelas Vaccine Product Portfolio
  42. 8.7.5 Hunan Zhong'an Biological Pharmaceutical Co., Ltd. Recent Developments
  43. 8.8 Chengdu Tianbang Biology
  44. 8.8.1 Chengdu Tianbang Biology Company Information
  45. 8.8.2 Chengdu Tianbang Biology Business Overview
  46. 8.8.3 Chengdu Tianbang Biology Swine Erysipelas Vaccine Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 Chengdu Tianbang Biology Swine Erysipelas Vaccine Product Portfolio
  48. 8.8.5 Chengdu Tianbang Biology Recent Developments
  49. 8.9 Zoetis
  50. 8.9.1 Zoetis Company Information
  51. 8.9.2 Zoetis Business Overview
  52. 8.9.3 Zoetis Swine Erysipelas Vaccine Sales, Value and Gross Margin (2021-2026)
  53. 8.9.4 Zoetis Swine Erysipelas Vaccine Product Portfolio
  54. 8.9.5 Zoetis Recent Developments
  55. 8.10 Boehringer Ingelheim
  56. 8.10.1 Boehringer Ingelheim Company Information
  57. 8.10.2 Boehringer Ingelheim Business Overview
  58. 8.10.3 Boehringer Ingelheim Swine Erysipelas Vaccine Sales, Value and Gross Margin (2021-2026)
  59. 8.10.4 Boehringer Ingelheim Swine Erysipelas Vaccine Product Portfolio
  60. 8.10.5 Boehringer Ingelheim Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Swine Erysipelas Vaccine Value Chain Analysis
  2. 9.1.1 Swine Erysipelas Vaccine Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Swine Erysipelas Vaccine Sales Mode & Process
  6. 9.2 Swine Erysipelas Vaccine Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Swine Erysipelas Vaccine Distributors
  9. 9.2.3 Swine Erysipelas Vaccine Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst